Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, announced the close of a $60 million USD Series B funding round. The financing will accelerate growth of Corvidia’s ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas. Venrock led the Series B financing and was joined by five additional new investors, including Andera Partners’ biotech franchise, BioDiscovery To read Corvidia Therapeutics’ press relase, click here